Literature DB >> 24878926

Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.

Abdolreza Malek1, Seyed-Reza Raeeskarami, Vahid Ziaee, Yahya Aghighi, Mohamad-Hassan Moradinejad.   

Abstract

This study evaluated the clinical features, course, and outcomes of Iranian children with juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and other uncommon connective tissue disorders. A chart review of 85 Iranian children with JDM and JPM was performed during a 10-year period from 2003 to 2013. The patients' clinical signs and symptoms, laboratory data, and other factors affecting clinical outcomes were recorded using questionnaires. Statistical analysis was performed using SPSS software version 20. In all, 40 boys and 45 girls were included in the study (F/M, 1.1:1). Disease frequency was significantly higher in boys aged <5 years (F/M, 0.4:1) and girls aged >5 years (F/M, 1.6:1). The combined mean age at diagnosis was 7.5 years. Muscle weakness, particularly in the proximal muscles of lower extremities (96 %); fatigue (83 %); and heliotrope rash (71 %) were the most frequently recorded symptoms. Elevated lactate dehydrogenase level was the most common enzyme disturbance (98 %). Monocyclic course was seen in 60 % of patients. The mean treatment duration was 3 years. The incidence rate of complications such as calcinosis, lipodystrophy, and growth disturbances was 20, 9, and 30 %, respectively. The occurrence of these complications in patients with monocyclic disease was significantly lower. Vital organ involvement led to the death of four patients. The incidence of calcinosis was significantly lower in patients having a shorter interval between disease onset and treatment. Two important complications, failure to thrive and lipodystrophy, were significantly higher in patients having antinuclear antibodies. The incidence of the above three complications was higher in patients with polycyclic or continuous chronic disease. Respiratory failure was the most common cause of patient mortality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24878926     DOI: 10.1007/s10067-014-2675-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

3.  Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.

Authors:  Elizabeth Stringer; John Bohnsack; Suzanne L Bowyer; Thomas A Griffin; Adam M Huber; Bianca Lang; Carol B Lindsley; Sylvia Ota; Clarissa Pilkington; Ann M Reed; Rosie Scuccimarri; Brian M Feldman
Journal:  J Rheumatol       Date:  2010-07-01       Impact factor: 4.666

4.  The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.

Authors:  L J McCann; A D Juggins; S M Maillard; L R Wedderburn; J E Davidson; K J Murray; C A Pilkington
Journal:  Rheumatology (Oxford)       Date:  2006-03-27       Impact factor: 7.580

5.  Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.

Authors:  Angelo Ravelli; Lucia Trail; Cristina Ferrari; Nicolino Ruperto; Angela Pistorio; Clarissa Pilkington; Susan Maillard; Sheila K Oliveira; Flavio Sztajnbok; Ruben Cuttica; Matilde Beltramelli; Fabrizia Corona; Maria Martha Katsicas; Ricardo Russo; Virginia Ferriani; Ruben Burgos-Vargas; Silvia Magni-Manzoni; Eunice Solis-Valleoj; Marcia Bandeira; Francesco Zulian; Vicente Baca; Elisabetta Cortis; Fernanda Falcini; Maria Alessio; Maria Giannina Alpigiani; Valeria Gerloni; Claudia Saad-Magalhaes; Rosanna Podda; Clovis A Silva; Loredana Lepore; Enrico Felici; Federica Rossi; Elena Sala; Alberto Martini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-01-15       Impact factor: 4.794

6.  Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Adam Schiffenbauer; Ira N Targoff; Karen Malley; Janardan P Pandey; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2008-10

7.  The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis.

Authors:  M S Klein-Gitelman; T Waters; L M Pachman
Journal:  Arthritis Care Res       Date:  2000-12

8.  Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Aneel Gursahaney; Ka-Leung Ngai; Jennifer A Daru; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02-15

Review 9.  Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes.

Authors:  A V Ramanan; Brian M Feldman
Journal:  Rheum Dis Clin North Am       Date:  2002-11       Impact factor: 2.670

10.  Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.

Authors:  Anjali Patwardhan; Robert Rennebohm; Igor Dvorchik; Charles H Spencer
Journal:  Pediatr Rheumatol Online J       Date:  2012-09-20       Impact factor: 3.054

View more
  4 in total

1.  Juvenile dermatomyositis: a tertiary center experience.

Authors:  Kenan Barut; Pinar Ozge Avar Aydin; Amra Adrovic; Sezgin Sahin; Ozgur Kasapcopur
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

2.  Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.

Authors:  Kathryn Phillippi; Mark Hoeltzel; Angela Byun Robinson; Susan Kim
Journal:  J Pediatr       Date:  2017-03-03       Impact factor: 4.406

Review 3.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

4.  Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.

Authors:  Amir B Orandi; Vikas R Dharnidharka; Noor Al-Hammadi; Kevin W Baszis
Journal:  Pediatr Rheumatol Online J       Date:  2018-12-29       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.